


Bone Medical

ASX/MEDIA RELEASE

BONE MEDICAL LIMITED RESULTS OF GENERAL MEETING

30 June 2011: Bone Medical Limited (ASX: BNE) advises, in relation to the General Meeting held today and in accordance with ASX Listing Rule 3.13.2 and section 251AA of the Corporations Act, details of the resolutions and proxies received.

		For	Against	Open	Abstain
Resolution 1	Approval of issue of Shares and Options to Proxima Laboratory	1,440,035	4,750	53,979,839	Nil
Resolution 2	Approval of issue of Shares and Options to Proxima Concepts	1,440,035	4,750	53,979,839	Nil
Resolution 3	Approval of issue of Shares and Options to Dr Roger New	1,440,035	4,750	53,979,839	Nil
Resolution 4	Approval of issue of Shares and Options to Leif Jensen	1,440,035	4,750	53,979,839	Nil
Resolution 5	Approval of issue of Shares and Options to Prof Peter Brooks	1,440,035	4,750	53,979,839	Nil
Resolution 6	Approval of issue of Shares and Options to Mr Barry Walker M.D	1,440,035	4,750	53,979,839	Nil
Resolution 7	Approval of issue of Shares and Options to Leon Ivory	1,440,035	4,750	53,979,839	Nil
Resolution 8	Approval of issue of Shares and Options to Ivory & Co Pty Ltd	1,440,035	4,750	53,979,839	Nil
Resolution 9	Ratification of previous issue of Shares	1,440,035	4,750	53,979,839	Nil
Resolution 10	Ratification of previous issue of Shares	1,440,035	4,750	53,979,839	Nil
Resolution 11	Ratification of previous issue of Shares	1,440,035	4,750	53,979,839	Nil
Resolution 12	Ratification of previous issue of Shares	1,440,035	4,750	53,979,839	Nil
Resolution 13	Ratification of previous issue of Shares	1,440,035	4,750	53,979,839	Nil



Bone Medical

Enquiries:

Leif Jensen

Chairman

Mobile: +45 4052 0787

Australian Office: +61 8 9355 5123

Peter Young

CEO

Mobile: +1 201 841 9681

Leon Ivory

Director

Mobile: +61 419 428 264

Or visit: www.bonemedical.com

About Bone Medical Limited

Bone Medical Limited is an international biopharmaceutical company focused on developing significant new products for the growing market in the treatment of bone disease, especially osteoporosis and arthritis. The Company's product pipeline includes:

- Phase II clinical-stage programs for the oral delivery of two well-established peptides which have historically been limited to nasal or injectable delivery
 - o Capsitonin™ (oral calcitonin)
 - Osteoporosis
 - Osteoarthritis
 - o CaPTHymone™ (oral parathyroid hormone) for osteoporosis
- Novel, potential breakthrough preclinical-stage compounds
 - o BN006 – oral TNF-alpha inhibitor for rheumatoid arthritis (RA)
 - o BN007 – collagen tolerance & joint protection agent for RA
 - o BN005 & BN008 – bone cell regulation for osteoporosis